For a robust genetic diagnosis of CMT2 as well as CMT2 differentiation from Silver syndrome and dHMNV, seipin/BSCL2 mutation screening seems to be important, particularly in patients with apparently upper motor neuron and lower motor neuron involvement. This evidence concerns the gene BSCL2 and Autosomal dominant spastic paraplegia type 17.